The performance of companies tied to the drug's past presents a challenging investment landscape. While the initial surge generated substantial gains, generic alternatives have significantly impacted sales . Investing in related pharmaceutical businesses now requires a thorough assessment of patent protection , evolving medical changes, and the pot